Tumor suppressor pathways shape EGFR-driven lung tumor progression and response to treatment.

In vivo modeling combined with CRISPR/Cas9-mediated somatic genome editing has contributed to elucidating the functional importance of specific genetic alterations in human tumors. Our recent work uncovered tumor suppressor pathways that affect EGFR-driven lung tumor growth and sensitivity to tyrosine kinase inhibitors and reflect the mutational landscape and treatment outcomes in the human disease.
Competing Interests: K.P. is a co-inventor on a patent licensed to Molecular MD for EGFR T790M mutation testing (through MSKCC). K.P. has received Honoraria/Consulting fees from Takeda, NCCN, Novartis, Merck, AstraZeneca, Tocagen, Maverick Therapeutics and Dynamo Therapeutics and research support from AstraZeneca, D2G Oncology, Kolltan, Roche, Symphogen and Boehringer-Ingelheim. M.M.W. has received honoraria from Genentech, Merck, and Amgen. M.M.W. and D.A.P. have ownership interest in, and are founders, consultants, and advisory board members for, D2G Oncology Inc.
(© 2022 Taylor & Francis Group, LLC.)